News | December 30, 2021
Biological E gets nod to study Corbevax as a booster dose
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
The contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services, is part of an effort to ensure secure local supply and production capacity for critical products for pandemic preparedness
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
The facility at the Andhra Pradesh Medtech Zone is expected to be completed by Dec 2022
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
It will be marketed under the brand name Molunamax
In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
Flattish volume growth and subdued new launches were key factors for last month
Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant
Subscribe To Our Newsletter & Stay Updated
